- Amplifying downstream processing efficiency
- Flexible solutions for diverse modalities
- Intensified productivity
- Supplied in pre-packed columns
- Compatible with existing chromatography systems
We take your security very seriously and have put in place a number of measures that reduce the risk of the website being maliciously attacked. This means that sometimes content on our site will timeout.
Please try to complete the action again.
Please do not click back on your browser as this may cause further issues.
Cell and gene therapy modalities are magnitudes larger than small molecule or recombinant protein-based therapies. Legacy technologies are suitable for monoclonal antibodies but not for modalities such as lentiviral vectors, exosomes or plasmids. Our AstreAdept® technology has been developed to meet the needs of cell and gene therapy developers to accelerate the commercialization of novel therapies.
Higher recovery reduces pressure to expand upstream production
Higher capacity and faster runs compresses bioprocessing, positively impacting on process economics
Smaller devices reduce physical footprint, reducing facility to use, water usage and waste removal, leading to greener manufacturing
Purify larger modalities with higher productivity for downstream processing and bring the advantages of AstreAdept® to manufacturing scale